Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Frailty 5Neoplasms 3Lung Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Multiple Myeloma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Solid Neoplasm 1Sarcopenia 1Sarcoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hepatic Malignancies 1Hematopoietic and Lymphoid System Neoplasm 1Hematologic Neoplasms 1Hematologic Diseases 1Health Education 1Head and Neck Neoplasms 1Communication 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Carboplatin 9pembrolizumab 7Pemetrexed 7Radiotherapy 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiation 4Nivolumab 4Bevacizumab 4Platinum 3Paclitaxel 3Mastectomy, Segmental 3Cisplatin 3Biopsy 3fludarabine phosphate 2durvalumab 2capmatinib 2aldesleukin 2Taxes 2Radiotherapy, Conformal 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2Anterior Temporal Lobectomy 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Geriatric Assessment × 1 year × Clear all
NCT04533451 2025-06-13

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
101 enrolled 21 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡